Clinically meaningful benefit: Real world use compared against the American and European guidelines

Jessica J. Dreicer; Sham Mailankody; Farhad Fahkrejahani; Vinay Prasad

doi:10.1038/s41408-017-0009-8

Clinically meaningful benefit: Real world use compared against the American and European guidelines

Jessica J. Dreicer, Sham Mailankody, Farhad Fahkrejahani, Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Article number	645
Journal	Blood cancer journal
Volume	7
Issue number	12
DOIs	https://doi.org/10.1038/s41408-017-0009-8
State	Published - Dec 1 2017

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-017-0009-8

Cite this

@article{c5e61b185be5491d97523619d6274bf0,

title = "Clinically meaningful benefit: Real world use compared against the American and European guidelines",

author = "Dreicer, {Jessica J.} and Sham Mailankody and Farhad Fahkrejahani and Vinay Prasad",

note = "Funding Information: Dr. Dreicer and Fahkrejahani—none; Dr Mailankody reported serving as a principal investigator for clinical trials with research funding from Juno Therapeutics and Takeda Oncology. Dr Mailankody reported receiving personal fees for speaking at the Wedbush Pacgrow Healthcare Conference 2016. Dr Prasad{\textquoteright}s research is funded by the Laura and John Arnold Foundation. Dr Mailankody is supported in part by support grant/core grant P30 CA008748 from the National Cancer Institute Memorial Sloan Kettering Cancer Center.",

year = "2017",

month = dec,

day = "1",

doi = "10.1038/s41408-017-0009-8",

language = "English (US)",

volume = "7",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Clinically meaningful benefit

T2 - Real world use compared against the American and European guidelines

AU - Dreicer, Jessica J.

AU - Mailankody, Sham

AU - Fahkrejahani, Farhad

AU - Prasad, Vinay

N1 - Funding Information: Dr. Dreicer and Fahkrejahani—none; Dr Mailankody reported serving as a principal investigator for clinical trials with research funding from Juno Therapeutics and Takeda Oncology. Dr Mailankody reported receiving personal fees for speaking at the Wedbush Pacgrow Healthcare Conference 2016. Dr Prasad’s research is funded by the Laura and John Arnold Foundation. Dr Mailankody is supported in part by support grant/core grant P30 CA008748 from the National Cancer Institute Memorial Sloan Kettering Cancer Center.

PY - 2017/12/1

Y1 - 2017/12/1

UR - http://www.scopus.com/inward/record.url?scp=85037978035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037978035&partnerID=8YFLogxK

U2 - 10.1038/s41408-017-0009-8

DO - 10.1038/s41408-017-0009-8

M3 - Letter

C2 - 29238046

AN - SCOPUS:85037978035

SN - 2044-5385

VL - 7

JO - Blood cancer journal

JF - Blood cancer journal

IS - 12

M1 - 645

ER -

Clinically meaningful benefit: Real world use compared against the American and European guidelines

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this